Skip to main content
Download PDF

Different effects of medications for hypertension on renal function between patients with and without diabetes mellitus undergoing percutaneous coronary intervention: a retrospective single-center cohort study

BMC Cardiovascular Disorders volume 23, Article number: 509 (2023) Cite this article

Abstract

Background

Diabetes mellitus (DM) and hypertension are well-known atherosclerosis risk factors. Furthermore, renal dysfunction is a crucial risk factor for patients with coronary artery disease (CAD), and managing renal function in these patients is complicated because of comorbid conditions and potential side effects during treatment. Therefore, this study aimed to investigate the effect of medications for hypertension on renal function after percutaneous coronary intervention (PCI) between patients with and without DM with statins.

Methods

In 297 consecutive patients undergoing PCI for stable angina pectoris, cystatin C (CysC) was evaluated at baseline and 9 months after PCI, and the percent change in CysC (%CysC) was calculated. The association of worsening renal function (WRF: %CysC ≥ 0) and baseline characteristics, including medications, was assessed.

Results

Among 297 hypertensive patients with statins, 196 and 101 were with and without DM, respectively. Angiotensin-converting enzyme inhibitor (ACEI), angiotensin II receptor blocker, and β-blocker were prescribed in 56 (29%), 82 (42%), and 91 (46%) patients in the DM group, and 20 (20%), 52 (51%), and 52 (51%) in the non-DM group, respectively. The patients with WRF after PCI were 100 (51%) and 59 (58%) in the DM and non-DM groups (p = 0.261). Additionally, the %CysC had no significant differences between groups [median: 0%, interquartile range (IQR): -7.9% to 8.5% vs. median: 1.1%, IQR: -6.6% to 9.6%, p = 0.521]. Multivariate logistic analysis for WRF using relevant factors from univariate analysis showed that only β-blocker [odds ratio (OR): 2.76, 95% confidence interval (CI): 1.03–7.90, p = 0.048] was independently associated with WRF in the DM group whereas ACEI (OR: 0.07, 95% CI: 0.01–0.47, p = 0.012) was negatively correlated with WRF in the non-DM group.

Conclusion

The β-blocker was the independent risk factor for WRF in patients with DM in the late phase after PCI for stable angina pectoris, while the use of ACEI had a renoprotective effect in patients without DM.

Peer Review reports

Background

Recently, percutaneous coronary intervention (PCI) has become a pivotal treatment for patients with coronary artery disease (CAD), and complete revascularization via PCI has reportedly resulted in lower long-term mortality [1] even in patients with diabetes mellitus (DM) and multivessel coronary disease. However, acute kidney injury (AKI) after PCI is associated with an increase in mortality [2, 3], and Murata et al. also reported that persistent worsening renal function (WRF) is associated with a high incidence of all-cause mortality and major adverse cardiac events in patients who underwent PCI for acute coronary syndrome [4]. Moreover, chronic kidney disease (CKD) is an independent risk factor for cardiovascular events and all-cause mortality, predicting cardiovascular events as effectively as other established risk factors [5, 6].

We reported that angiotensin-converting enzyme inhibitors (ACEI) might have a preventive effect on WRF assessed by serum cystatin C (CysC) measurements in the late phase after PCI [7], and ACEI, angiotensin II receptor blockers (ARB), and β-blockers have been shown to lower cardiovascular mortality in the populations with cardiovascular disease. Statin therapy is also commonly used for the secondary prevention of cardiovascular disease. A previous study reported that statin therapy appears to reduce proteinuria and CKD progression rate [8]. Additionally, a meta-analysis of patients undergoing coronary angiography or PCI showed that short-term statin therapy reduced contrast-induced nephropathy (CIN) incidence and that the use of statins should be considered even in patients with reduced low-density lipoprotein cholesterol (LDL-C) levels [9]. However, previous studies reported that DM and hypertension were known as strong risk factors for the incidence of CIN.

Therefore, this study aimed to investigate the differences in the effects of medications on renal function in the late phase after PCI between hypertensive patients with and without DM among those with statins. Furthermore, we included additional patients following our previous report [7] and investigated the change in renal function before and 9 months after PCI by measuring serum CysC and factors affecting renal function.

Methods

Study population

This retrospective single-center cohort study included 297 consecutive patients with hypertension who underwent elective PCI for stable angina pectoris at Kagoshima University Hospital from January 2010 to July 2016. All patients received statin therapy regardless of dyslipidemia before the PCI procedure and underwent follow-up coronary angiography 9 months after PCI, excluding those who could not be tracked after discharge. Patients with cardiogenic shock or those treated with intra-aortic balloon pumping during PCI were excluded from this study since they are risk factors for AKI. Furthermore, patients undergoing hemodialysis were also excluded. This study was approved by the Research and Ethics Committee at Kagoshima University Hospital and was conducted in accordance with the ethical principles stated in the 1975 Declaration of Helsinki. All patients provided written informed consent before enrolment.

PCI procedure

All patients received dual antiplatelet therapy and intravenous heparin before the procedure. In patients with serum creatinine (Cr) levels > 1.2 mg/dL, intravenous hydration with normal saline was provided at 1 mL/kg/h for 12 h before and after PCI. A nonionic iso-osmolar contrast media was used during PCI. Finally, all patients underwent a follow-up coronary angiography 9 months after PCI.

Assessment of renal function

Laboratory values were obtained on admission before PCI. Serum CysC was measured using a colloidal gold particle-enhanced colorimetric immunoassay (Nescauto GC Cystatin C, Alfresa Pharma, Osaka, Japan). The estimated glomerular filtration rate (eGFR) was calculated using the Modification of Diet in Renal Disease equation, with coefficients modified for the Japanese population as follows: eGFR (mL/min/1.73 m2) = 194 × serum Cr (mg/dL)−1.094 × age (years)−0.287 (× 0.739 for female participants) [10]. The grade of renal function was classified based on the level of eGFR [11]. Serum concentrations of CysC were reassessed 9 months after PCI. We evaluated renal function change 9 months after PCI, which was defined as the late phase when patients received the follow-up coronary angiography. The percent change in CysC [%CysC = (CysC at 9 months—CysC at baseline)/CysC at baseline × 100] was calculated. Furthermore, %CysC ≥ 0% and %CysC < 0% after PCI were defined as WRF and non-WRF, respectively.

Definitions

DM was defined based on the following criteria: use of antihyperglycemic medication, fasting plasma glucose concentration > 126 mg/dL, or glycated hemoglobin concentration ≥ 6.5% (in accordance with the National Glycohemoglobin Standardization Program) [12].

Statistical analysis

Quantitative data are presented as mean ± standard deviation or median and interquartile range (IQR). Fisher’s exact test was used to compare the incidence of categorical variables, which are expressed as percentages. Continuous variables were compared between the DM and non-DM groups using Student’s t-test or the Wilcoxon rank-sum test for normal or non-normal distribution data, respectively. Univariate logistic regression analysis was performed using medication details known at the time of admission, patient background, and common comorbidities associated with cardiovascular disease as parameters. We performed multivariate logistic analysis for the presence of WRF using relevant factors from univariate analysis, with the results expressed as the odds ratio (OR) and 95% confidence interval (CI). Statistical significance was considered at p < 0.05, and statistical analyses were performed using SAS software (JMP® 16 (SAS Institute Inc., Cary, NC, USA).

Results

Baseline characteristics

Table 1 shows the baseline clinical characteristics of patients. Among 297 hypertensive patients with statins, 196 and 101 were with and without DM, respectively. Significant differences in diastolic blood pressure (median: 73 mmHg, IQR: 69–81 mmHg vs. median: 70 mmHg, IQR: 64–77 mmHg, p = 0.003), hemoglobin (median: 13.0 g/dL, IQR: 11.8–14.1 g/dL vs. median: 13.2 g/dL, IQR: 12.1–14.7 mg/dL, p = 0.030), high-density lipoprotein cholesterol (HDL-C) (median: 47 mg/dL, IQR: 38–54 mg/dL vs. median: 49 mg/dL, IQR 41–61 mg/dL, p = 0.025), fasting plasma glucose (median: 114 mg/dL, IQR: 99–148 mg/dL vs. median: 93 mg/dL, IQR: 89–106 mg/dL), p < 0.001, and glycated hemoglobin (median: 6.8%, IQR: 6.1–7.3% vs. median: 5.9%, IQR: 5.6–6.1%, p < 0.001) levels were found between the DM and non-DM groups.

Table 1 Patient characteristics
Full size table

ACEI and ARB were prescribed in 56 (29%) and 82 (42%) patients in the DM group and 20 (20%) and 52 (51%) in the non-DM group, respectively. However, no patients were taking both ACEI and ARB. Additionally, no significant differences in baseline eGFR, Cr, and CysC levels were found between the DM and non-DM groups, and the mean volume of contrast media did not differ between groups.

Association between DM and change in renal function

We compared the %CysC between groups, and no significant differences in the %CysC were found between the DM and non-DM groups (median: 0%, IQR: -7.9% to 8.5% vs. median: 1.1%, IQR: -6.6% to 9.6%, p = 0.521) (Fig. 1). The patients with WRF after PCI were 100 (51%) and 59 (58%) in the DM and non-DM groups, respectively (p = 0.261).

Fig. 1
figure 1

Comparison of the changes in cystatin C among patients with and without DM

Full size image

Influence of baseline characteristics on WRF after PCI in the DM and non-DM groups

Tables 2 and 3 present the results of univariate logistic analysis for WRF following PCI in the DM and non-DM groups. In the DM group, age (OR: 1.04, 95% CI: 1.01–1.08, p = 0.020) and the use of β-blocker (OR: 2.04, 95% CI: 1.16–3.63, p = 0.015) positively correlated with WRF. Body mass index (BMI) (OR: 0.89, 95% CI: 0.81–0.98, p = 0.019) and LDL-C (OR: 0.98, 95% CI: 0.97–0.99, p = 0.001) were negatively correlated with WRF (Table 2). However, BMI (OR: 1.16, 95% CI: 1.03–1.32, p = 0.016), systolic blood pressure (OR: 1.02, 95% CI: 1.01–1.06, p = 0.047), calcium channel blocker (OR: 3.36, 95% CI: 1.48–7.89, p = 0.004), and ARB (OR: 2.54, 95% CI: 1.14–5.83, p = 0.025) positively correlated with WRF in the non-DM group. ACEI negatively correlated with WRF (OR: 0.30, 95% CI: 0.10–0.82, p = 0.021) (Table 3). In multivariate logistic analysis for WRF after PCI using relevant factors from univariate analysis including contrast media which was generally considered as a risk factor for renal dysfunction, the use of β-blocker (OR: 2.76, 95% CI: 1.03–7.90, p = 0.048) and ACEI (OR: 0.07, 95% CI: 0.01–0.47, p = 0.012) were independently correlated with WRF in the DM and non-DM groups, respectively (Tables 2 and 3).

Table 2 Logistic regression analyses for WRF in the DM group
Full size table
Table 3 Logistic regression analyses for WRF in non-DM group
Full size table

Discussion

This study demonstrated that the use of β-blockers positively correlated with WRF in the DM group, whereas ACEI negatively correlated with WRF in the non-DM group. This study underscored the different effects of pre-medications on the WRF after PCI between hypertensive patients with and without DM who received treatment with statins.

Previous studies reported that WRF after PCI, including CIN, is a powerful predictor of cardiovascular events and mortality [2, 3, 13,14,15]. Therefore, preventing WRF after PCI is important to improve prognosis. Renin–angiotensin–aldosterone (RAS) inhibitors are believed to have a renoprotective effect [16]. Additionally, in the NAPLES II trial, CIN prevalence, defined as a > 10% increase in serum CysC, was lower in the atorvastatin group than in the control group [17]. Therefore, statins might also prevent renal dysfunction after using contrast media. DM is well-known as a significant risk factor for CAD and increases overall morbidity and mortality [18]. In patients with DM, renal function is also severely affected due to arteriosclerosis and diabetic nephropathy, and diabetic kidneys are characterized by severe interstitial inflammation [19]. Moreover, DM is believed to be a high-risk factor for developing CIN [20], and several studies have reported that the persistence of renal dysfunction with CIN results in poor prognosis [21]. Therefore, we focused on the impact of medications, including RAS inhibitors, on renal functions in hypertensive patients with DM taking statins.

We previously reported that ACEI had a renoprotective effect in the late phase after PCI rather than ARB [7]. In our report, we considered nitric oxide (NO) a key factor in protecting renal function. ACEI inhibits angiotensin II formation and bradykinin potentiation and increases NO. Interestingly, NO is involved in vascular endothelial function and might be considered to have a renoprotective effect. Furthermore, statins have also been reported to upregulate NO synthase [22, 23] and reduce oxidative stress, which may reduce the progression of renal dysfunction. In this study, we demonstrated that ACEI exhibited a renoprotective effect in the late phase after PCI in patients without DM rather than in those with DM. It was considered that patients with DM had a stronger disorder of NO production than those without DM. Atherosclerosis is characterized by an early reduction in NO [24], and coronary risk factors such as hyperlipidemia and DM are known to impair NO function, which becomes severe with the increase in the number of risk factors. Particularly, DM, characterized by insulin resistance, is associated with an acceleration of atherosclerotic vascular disease and poor outcomes following vascular interventions and is believed to be caused by increasing inflammation and decreasing NO bioavailability [25, 26]. Meininger et al. reported that high glucose levels increase NO synthase (NOS)-dependent superoxide production in human endothelial cells and mediate endothelial NOS dysfunction in endothelial cells [27]. Furthermore, glycated hemoglobin (HbA1c) which showed the long-term glycemic index was positively associated with the severity of CAD even in non-diabetic individuals [28]. We speculated that patients with DM may have severer endothelial dysfunction than those without DM, which may have caused the different effects of ACEI on renal function between patients with and without DM in this study.

Hypertension is an important risk factor for cardiovascular events regardless of its type or presence of left ventricular hypertrophy [29,30,31]. Furthermore, blood pressure control is associated with several parameters as known to risk factors of coronary artery disease and other cardiac diseases [32, 33]. Therefore, blood pressure control through medication has important implications for the prognosis of heart disease. β-blockers have an important dual role, such as antihypertensive effect and providing optimal cardiovascular protection in patients with hypertension. They are also important drugs for optimal medical therapy for ischemic heart disease. However, to our knowledge, only a few published reports of β-blockers-associated kidney injury after PCI. In our study, we found that β-blockers were the independent risk factor for WRF in the late phase after PCI in hypertensive patients with DM taking statins. There might be a few potential mechanisms in this association between β-blockers and WRF. The effect of the lowering heart rate by β-blockers will play an important role for heart failure. However, the decrease in heart rate may lead to relatively higher central aortic systolic pressure which induce the negative effect on renal function [34]. In addition, animal and cell biology studies showed that β-blockers could have profibrotic effects due to activate the production of TGF-β and collagen I and III [35]. Furthermore, β-blockers reportedly worsen insulin sensitivity, alter lipid metabolism, and cause weight gain [36]. Disorders of insulin sensitivity and lipid metabolism have also been reported to result in endothelial dysfunction. Owing to those mechanisms, using β-blockers might worsen renal function in patients with DM. We summarized the results of this study and previous reports which we have referenced in this study in Table 4.

Table 4 Summary of this study and previous reports for renal function and endothelial function
Full size table

Currently, there is insufficient evidence of the benefit of β-blockers use for stable angina pectoris patients without left ventricular dysfunction. In addition, β-blockers are not first-line agents for hypertensive patients. Based on the results of the present study, we believe that careful consideration should be needed to use β-blockers in DM patients complicated stable angina pectoris who require PCI, except in patients with left ventricular dysfunction who could clearly benefit from use of β-blockers.

This study had some limitations. First, all subjects underwent elective PCI and follow-up coronary angiography 9 months after PCI at our hospital and this study was a retrospective study with a relatively small number of patients. Therefore, a large-scale prospective study should assess the effect of ACEI and β-blockers on renal function over a longer time after PCI. Second, only patients with mild to moderate renal dysfunction were recruited in this study. Therefore, the impact of ACEI and β-blockers on renal function in the late phase after PCI in patients with severe renal dysfunction should be investigated. Third, all medications that the patients took were checked at the time of admission. However, we could not completely confirm that the patients took all medicines regularly during study period.

Conclusions

The use of β-blockers was the independent risk factor for WRF in hypertensive patients with DM in the late phase after PCI for stable angina pectoris who underwent statin therapy, whereas ACEI had a renoprotective effect in patients without DM.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author upon reasonable request.

Abbreviations

ACEI:

Angiotensin-converting enzyme inhibitor

DM:

Diabetes mellitus

CAD:

Coronary artery disease

PCI:

Percutaneous intervention

CysC:

Cystatin

%CysC:

Percent change in cCysC

OR:

Odds ratio

CI:

Confidence interval

IQR:

Interquartile range

WRF:

Worsening renal function

AKI:

Acute kidney injury

CKD:

Chronic kidney disease

ARB:

Angiotensin II receptor blockers

CIN:

Contrast-induced nephropathy

LDL-C:

Low-density lipoprotein cholesterol

Cr:

Creatinine

eGFR:

Estimated glomerular filtration rate

HDL-C:

High-density lipoprotein cholesterol

BMI:

Body mass index

RAS:

Renin–angiotensin–aldosterone

NO:

Nitric oxide

NOS:

NO synthase

References

  1. Jiménez-Navarro MF, López-Jiménez F, Barsness G, Lennon RJ, Sandhu GS, Prasad A. Long-term prognosis of complete percutaneous coronary revascularization in patients with diabetes with multivessel disease. Heart. 2015;101:1233–9.

    Article  PubMed  Google Scholar 

  2. McCullough PA, Wolyn R, Rocher LL, Levin RN, O’Neill WW. Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality. Am J Med. 1997;103:368–75.

    Article  PubMed  CAS  Google Scholar 

  3. Rihal CS, Textor SC, Grill DE, Berger PB, Ting HH, Best PJ, et al. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation. 2002;105:2259–64.

    Article  PubMed  Google Scholar 

  4. Murata N, Kaneko H, Yajima J, Oikawa Y, Oshima T, Tanaka S, et al. The prognostic impact of worsening renal function in Japanese patients undergoing percutaneous coronary intervention with acute coronary syndrome. J Cardiol. 2015;66:326–32.

    Article  PubMed  Google Scholar 

  5. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351:1296–305.

    Article  PubMed  CAS  Google Scholar 

  6. Aktan A, Güzel T. Prognostic value of age, creatinine, and left ventricular ejection fraction risk score in patients evaluated with fractional flow reserve: a cross-sectional study. Rev Assoc Med Bras (1992). 2023;21(69):e20230533.

    Article  Google Scholar 

  7. Kanda D, Takumi T, Miyata M, Tokushige A, Sonoda T, Yoshino S, et al. Angiotensin-converting enzyme inhibitor prevents the worsening of renal function in the late phase after percutaneous coronary intervention. J Atheroscler Thromb. 2016;23:233–40.

    Article  PubMed  CAS  Google Scholar 

  8. Sandhu S, Wiebe N, Fried LF, Tonelli M. Statins for improving renal outcomes: a meta-analysis. J Am Soc Nephrol. 2006;17:2006–16.

    Article  PubMed  CAS  Google Scholar 

  9. Barbieri L, Verdoia M, Schaffer A, Nardin M, Marino P, De Luca G. The role of statins in the prevention of contrast induced nephropathy: a meta-analysis of 8 randomized trials. J Thromb Thrombolysis. 2014;38:493–502.

    Article  PubMed  CAS  Google Scholar 

  10. Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J kidney Dis. 2009;53:982–92.

    Article  PubMed  CAS  Google Scholar 

  11. KDIGO. clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2012;2013(3):1–150.

    Google Scholar 

  12. The International Expert Committee. International Expert Committee Report on the role of the A1c assay in the diagnosis of diabetes. Diabetes Care. 2009;32:1327–33.

    Article  PubMed Central  Google Scholar 

  13. Best PJ, Lennon R, Ting HH, Bell MR, Rihal CS, Holmes DR, et al. The impact of renal insufficiency on clinical outcomes in patients undergoing percutaneous coronary interventions. J Am Coll Cardiol. 2002;39:1113–9.

    Article  PubMed  Google Scholar 

  14. Gupta R, Gurm HS, Bhatt DL, Chew DP, Ellis SG. Renal failure after percutaneous coronary intervention is associated with high mortality. Catheter Cardiovasc Interv. 2005;64:442–8.

    Article  PubMed  Google Scholar 

  15. Güzel T, Aktan A, Demir M, Özbek M, Aslan B. Relationship between contrast-induced nephropathy and long-term mortality after percutaneous coronary intervention in patients with chronic coronary total occlusion. Rev Assoc Med Bras. 1992;2022(68):1078–83.

    Google Scholar 

  16. Zandi-Nejad K, Brenner BM. Primary and secondary prevention of chronic kidney disease. J Hypertens. 2005;23:1771–6.

    Article  PubMed  CAS  Google Scholar 

  17. Quintavalle C, Fiore D, De Micco F, Visconti G, Focaccio A, Golia B, et al. Impact of a high loading dose of atorvastatin on contrast-induced acute kidney injury. Circulation. 2012;126:3008–16.

    Article  PubMed  CAS  Google Scholar 

  18. Bertoluci MC, Rocha VZ. Cardiovascular risk assessment in patients with diabetes. Diabetol Metab Syndr. 2017;9:25.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Najafian B, Alpers CE, Fogo AB. Pathology of human diabetic nephropathy. Contrib Nephrol. 2011;170:36–47.

    Article  PubMed  Google Scholar 

  20. Toprak O, Cirit M, Yesil M, Bayata S, Tanrisev M, Varol U, et al. Impact of diabetic and pre-diabetic state on development of contrast-induced nephropathy in patients with chronic kidney disease. Nephrol Dial Transplant. 2007;22:819–26.

    Article  PubMed  Google Scholar 

  21. McCullough PA, Adam A, Becker CR, Davidson C, Lameire N, Stacul F, et al. Epidemiology and prognostic implications of contrast-induced nephropathy. Am J Cardiol. 2006;98:5K-13K.

    Article  PubMed  CAS  Google Scholar 

  22. Athyros VG, Kakafika AI, Tziomalos K, Karagiannis A, Mikhailidis DP. Pleiotropic effects of statins–clinical evidence. Curr Pharm Des. 2009;15:479–89.

    Article  PubMed  CAS  Google Scholar 

  23. O’Driscoll G, Green D, Taylor RR. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation. 1997;95:1126–31.

    Article  PubMed  CAS  Google Scholar 

  24. Chen JY, Ye ZX, Wang XF, Chang J, Yang MW, Zhong HH, et al. Nitric oxide bioavailability dysfunction involves in atherosclerosis. Biomed Pharmacother. 2017;97:423–8.

    Article  PubMed  Google Scholar 

  25. Barbato JE, Zuckerbraun BS, Overhaus M, Raman KG, Tzeng E. Nitric oxide modulates vascular inflammation and intimal hyperplasia in insulin resistance and the metabolic syndrome. Am J Physiol Heart Circ Physiol. 2005;289:228–36.

    Article  Google Scholar 

  26. Karakayali M, Omar T, Artac I, Rencuzogullari İ, Karabag Y, Demir O. The relationship between the systemic immune-inflammation index and reverse-dipper circadian pattern in newly diagnosed hypertensive patients. J Clin Hypertens (Greenwich). 2023;25:700–7.

    Article  PubMed  Google Scholar 

  27. Meininger CJ, Marinos RS, Hatakeyama K, Martinez-Zaguilan R, Rojas JD, Kelly KA, et al. Impaired nitric oxide production in coronary endothelial cells of the spontaneously diabetic BB rat is due to tetrahydrobiopterin deficiency. Biochem J. 2000;349:353–6.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  28. Kis M, Guzel T. Relationship between hemoglobin A1c and fractional flow reserve lesion severity in non-diabetic patients. J Coll Physicians Surg Pak. 2022;32:4–8.

    Article  PubMed  Google Scholar 

  29. Karakayali M, Artac I, Omar T, Rencuzogullari İ, Karabag Y, Cinar T, et al. The association between frontal QRS-T angle and reverse dipper status in newly diagnosed hypertensive patients. Blood Press Monit. 2023;28:96–102.

    Article  PubMed  Google Scholar 

  30. Altunova M, Püşüroğlu H, Karakayalı M, Şahin AA, Demir AR, Yılmaz E, et al. Relationship between fragmented QRS complex and long-term cardiovascular outcome in patients with essential hypertension. Anatol J Cardiol. 2022;26:442–9.

    Article  PubMed  PubMed Central  Google Scholar 

  31. Kis M, Dogan Y, Yildirim A, Güzel T, Bekar L, Akhan O, et al. Evaluation of demographic, clinical, and aetiological data of patients admitted to cardiology clinics and diagnosed with left ventricular hypertrophy in Turkish population (LVH-TR). Acta Cardiol. 2022;77:836–45.

    Article  PubMed  CAS  Google Scholar 

  32. Aktas G, Khalid A, Kurtkulagi O, Duman TT, Bilgin S, Kahveci G, et al. Poorly controlled hypertension is associated with elevated serum uric acid to HDL-cholesterol ratio: a cross-sectional cohort study. Postgrad Med. 2022;134:297–302.

    Article  PubMed  CAS  Google Scholar 

  33. Mansiroglu AK, Coşgun M, Sincer I, Gunes Y. The role of baseline and post-treatment frontal QRS-T angle for detecting arterial blood pressure control. Clin Exp Hypertens. 2021;43:363–7.

    Article  PubMed  CAS  Google Scholar 

  34. Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, LIFE Study Group, et al. Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:995–1003.

    Article  PubMed  Google Scholar 

  35. Akutsu S, Shimada A, Yamane A. Transforming growth factor betas are upregulated in the rat masseter muscle hypertrophied by clenbuterol, a beta2 adrenergic agonist. Br J Pharmacol. 2006;147:412–21.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  36. Manrique C, Johnson M, Sowers JR. Thiazide diuretics alone or with beta-blockers impair glucose metabolism in hypertensive patients with abdominal obesity. Hypertension. 2010;55:15–7.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

We thank the staff of the Department of Cardiovascular Medicine and Hypertension for their assistance with data processing.

Funding

This work was partly supported by the Japan Society for the Promotion of Science KAKENHI (grant no. 16H070890).

Author information

Authors and Affiliations

  1. Department of Cardiovascular Medicine and Hypertension, Graduate School of Medical and Dental Sciences, Kagoshima University, 8-35-1 Sakuragaoka, Kagoshima City, Kagoshima, 890-8520, Japan

    Daisuke Kanda, Takuro Takumi, Akihiro Tokushige, Yoshiyuki Ikeda & Mitsuru Ohishi

Authors
  1. Daisuke Kanda
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Takuro Takumi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Akihiro Tokushige
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yoshiyuki Ikeda
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Mitsuru Ohishi
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

DK and AT analyzed the data; DK wrote the manuscript; TT and YI revised the manuscript; and MO drafted the work. All authors have read and approved the manuscript.

Corresponding author

Correspondence to Daisuke Kanda.

Ethics declarations

Ethics approval and consent to participate

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. All patients provided written informed consent before enrolment. This study was approved by the Research and Ethics Committee at Kagoshima University Hospital.

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kanda, D., Takumi, T., Tokushige, A. et al. Different effects of medications for hypertension on renal function between patients with and without diabetes mellitus undergoing percutaneous coronary intervention: a retrospective single-center cohort study. BMC Cardiovasc Disord 23, 509 (2023). https://doi.org/10.1186/s12872-023-03547-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12872-023-03547-7

Keywords

BMC Cardiovascular Disorders

ISSN: 1471-2261

Contact us